Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,339 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Dyne Therapeutics Trading Up 0.5 %
DYN stock opened at $36.59 on Friday. Dyne Therapeutics, Inc. has a one year low of $6.40 and a one year high of $47.45. The firm has a 50-day moving average of $41.07 and a two-hundred day moving average of $33.55. The firm has a market capitalization of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Dyne Therapeutics
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new position in Dyne Therapeutics in the 4th quarter worth about $304,000. Rafferty Asset Management LLC grew its stake in shares of Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after buying an additional 24,632 shares in the last quarter. Commodore Capital LP acquired a new position in Dyne Therapeutics in the fourth quarter worth approximately $11,970,000. Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics during the fourth quarter valued at approximately $15,758,000. Finally, Octagon Capital Advisors LP lifted its stake in Dyne Therapeutics by 14.4% in the fourth quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock valued at $10,546,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Five stocks we like better than Dyne Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to Invest in Small Cap Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What Are the U.K. Market Holidays? How to Invest and Trade
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.